

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(12) UK Patent Application (19) GB (11) 2 269 590 (13) A

(43) Date of A Publication 16.02.1994

(21) Application No 9315962.2

(22) Date of Filing 02.08.1993

(30) Priority Data

(31) 9216911.9 (32) 10.08.1992 (33) GB

(71) Applicant(s)

Merck Sharp & Dohme Limited

(Incorporated in the United Kingdom)

Hertford Road, HODDESDON, Hertfordshire,
EN11 9BU, United Kingdom

(72) Inventor(s)

Fintan Kelleher

Richard Thomas Lewis

(74) Agent and/or Address for Service

H K Quillin

Merck & Co Inc, European Patent Department,
Terlings Park Eastwick Road, HARLOW, Essex,
CM20 2QR, United Kingdom

(51) INT CL⁵

C07D 215/20, A61K 31/47

(52) UK CL (Edition M)

C2C CAA CBE CWE C1534 C213 C22Y C220 C228 C25Y
C250 C251 C29X C29Y C31Y C311 C36Y C364 C366
C368 C43X C50Y C500 C624 C628 C65X C672 C678
C694 C699 C778 C80Y C802
U1S S1313 S1318 S1321 S2411 S2414 S2415 S2416
S2417 S2418

(56) Documents Cited

None

(58) Field of Search


UK CL (Edition L) C2C CBE CWE

INT CL⁵ C07D

ONLINE DATABASE: CAS ONLINE

(54) Azabicyclic compounds

(57) Compounds of formula (I), and salts and prodrugs thereof:



(I)

wherein

X represents O or S;

Y represents $(CH_2)_m$, where m is 0 or 1;

Z represents $(CH_2)_n$, where n is 0 or 1;

R¹ represents optionally substituted phenyl;

R² is phenyl, naphthyl, indazolyl, thienyl, furyl, pyridyl, thiazolyl, tetrazolyl, quinolyl, benzhydryl or benzyl;

R³ is H, COR^a, CO₂ R^a, C(COOR^a)₂, C(CONR^aR^b)₂, COCONR^aR^b, COCO₂ R^a, C₁₋₆ alkyl optionally substituted by a group selected from (CO₂ R^a, CONR^aR^b, hydroxy, cyano, COR^a, NR^aR^b, C(NOH)NR^aR^b, CONHphenyl(C₁₋₄ alkyl), COCO₂ R^a, C(=NR^a)NR^bNR^cCO₂ R^d, CONHNR^aR^b, C(S)NR^aR^b, CONR^aC₁₋₆ alkylR¹², CONR¹³C₂₋₆ alkynyl, CONR¹³C₂₋₆ alkenyl, COCONR^aR^b, CONR^aC(NR^b)NR^cR^d, CONR¹³SO₂ R^a, SO₂ R¹³COR^a, COR^a, CONR^aheteroaryl, and optionally substituted phenyl or C₁₋₆ alkyl, optionally substituted by oxo, substituted by an optionally substituted aromatic heterocycle;

Each R⁴ is halo, C₁₋₆ alkyl, C₁₋₆ alkoxy or trifluoromethyl;

R⁵ and R⁶ are H or C₁₋₆ alkyl;

R^a, R^b, R^c and R^d are H, C₁₋₆ alkyl, phenyl or trifluoromethyl;

R¹² represents OR^a, CONR^aR^b or heteroaryl;

R¹³ represents H or C₁₋₆ alkyl;

R^q represents a group



where Q represents the residue of a non-aromatic azacyclic or azabicyclic ring system; and
x is 0, 1, 2 or 3; are tachykinin antagonists useful in therapy.

GB 2 269 590 A

- 1 -

AZABICYCLIC COMPOUNDS

5 This invention relates to a class of
azabicyclic compounds, which are useful as tachykinin
antagonists. More particularly, the compounds of the
invention comprise an azacyclic ring system, having a
fused benzene ring, substituted by an arylmethoxy or
arylmethylthio moiety.

10 The tachykinins are a group of naturally-
occurring peptides found widely distributed throughout
mammalian tissues, both within the central nervous system
and in the peripheral nervous and circulatory systems.
The three known mammalian tachykinins are:
15 substance P, neurokinin A and neurokinin B:


Evidence for the usefulness of tachykinin
receptor antagonists in pain, headache, especially
migraine, Alzheimer's disease, multiple sclerosis,
attenuation of morphine withdrawal, cardiovascular
20 changes, oedema, such as oedema caused by thermal injury,
chronic inflammatory diseases such as rheumatoid
arthritis, asthma/bronchial hyperreactivity and other
respiratory diseases including allergic rhinitis,
inflammatory diseases of the gut including ulcerative
25 colitis and Crohn disease, ocular injury and ocular
inflammatory diseases, proliferative vitreoretinopathy,
irritable bowel syndrome and disorders of bladder
function including cystitis and bladder detruser hyper-
reflexia is reviewed in "Tachykinin Receptors and
30 Tachykinin Receptor Antagonists", C.A. Maggi, R.
Patacchini, P. Rovero and A. Giachetti, J. Auton.
Pharmacol. (1993) 13, 23-93. Tachykinin antagonists are
also believed to be useful in allergic conditions
[Hamelet et al Can. J. Pharmacol. Physiol. (1988) 66

1361-7], immunoregulation [Lotz et al Science (1988) 241
1218-21 and Kimball et al, J. Immunol. (1988) 141 (10)
3564-9], and as anticonvulsants [Garant et al., Brain
Research (1986) 382 372-8]. Tachykinin antagonists may
5 also be useful in the treatment of small cell carcinomas,
in particular small cell lung cancer (SCLC) [Langdon et
al., Cancer Research (1992) 52, 4554-7].

It has furthermore been suggested that
tachykinins have utility in the following disorders:
10 depression, dysthymic disorders, chronic obstructive
airways disease, hypersensitivity disorders such as
poison ivy, vasospastic diseases such as angina and
Reynauld's disease, fibrosing and collagen diseases such
as scleroderma and eosinophillic fascioliasis, reflex
15 sympathetic dystrophy such as shoulder/hand syndrome,
addiction disorders such as alcoholism, stress related
somatic disorders, neuropathy, neuralgia, disorders
related to immune enhancement or suppression such as
systemic lupus erythmatosis (European patent application
20 no. 0 436 334), conjunctivitis, vernal conjunctivitis,
contact dermatitis, atropic dermatitis, urticaria, and
other eczematoid dermatitis (European patent application
no. 0 394 989) and emesis (European patent application
no. 0 533 280).

25 WO-A-90/05729, WO-A-91/18899 and WO-A-92/12151
disclose 3-[cyclic]methyldamino-2-[(α -substituted)-
arylmethyl]quinuclidine compounds which are stated to be
useful as substance P antagonists. EP-A-0 436 334
discloses 3-aminopiperidine derivatives as substance P
30 antagonists, and WO-92/06079 discloses related fused
bicyclic compounds, also as substance P antagonists.
There is no disclosure of azacycles having a fused
benzene ring.

The present invention provides a compound of formula (I), or a salt or prodrug thereof:



(I)

wherein

X represents O or S;

Y represents $(CH_2)_m$, where m is 0 or 1;

15 Z represents $(CH_2)_n$, where n is 0 or 1;

R^1 represents phenyl optionally substituted by

1, 2 or 3 groups selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, $-OR^a$, SR^a , SOR^a , SO_2R^a , $-NR^aR^b$, $-NR^aCOR^b$,
20 $-NR^aCO_2R^b$, $-CO_2R^a$ and $-CONR^aR^b$;

R^2 represents aryl selected from phenyl and naphthyl; heteroaryl selected from indazolyl, thienyl, furyl, pyridyl, thiazolyl, tetrazolyl and quinolyl; benzhydryl; or benzyl; wherein each aryl or heteroaryl
25 moiety may be substituted by C_{1-6} alkyl, C_{1-6} alkoxy, halo or trifluoromethyl;

R^3 represents H, COR^a , CO_2R^a , $C(COOR^a)_2$, $C(CONR^aR^b)_2$, $COCONR^aR^b$, $COCO_2R^a$, C_{1-6} alkyl optionally substituted by a group selected from $(CO_2R^a$, $CONR^aR^b$, hydroxy, cyano, COR^a , NR^aR^b , $C(NOH)NR^aR^b$,
30 $CONHphenyl(C_{1-4}alkyl)$, $COCO_2R^a$, $C(=NR^a)NR^bNR^cCO_2R^d$, $CONHNR^aR^b$, $C(S)NR^aR^b$, $CONR^aC_{1-6}alkylR^{12}$, $CONR^{13}C_{2-6}alkynyl$, $CONR^{13}C_{2-6}alkenyl$, $COCONR^aR^b$, $CONR^aC(NR^b)NR^cR^d$, $CONR^{13}SO_2R^a$, $SO_2R^{13}COR^a$, COR^q ,

CONR^aheteroaryl, and phenyl optionally substituted by one or more substituents selected from C₁₋₆alkyl, C₁₋₆alkoxy, halo and trifluoromethyl) or C₁₋₆alkyl, optionally substituted by oxo, substituted by an optionally substituted aromatic heterocycle;

Each R⁴ independently represents halo, C₁₋₆alkyl, C₁₋₆alkoxy or trifluoromethyl; R⁵ and R⁶ each independently represent H or C₁₋₆alkyl;

R^a, R^b, R^c and R^d each independently represent H, C₁₋₆alkyl, phenyl or trifluoromethyl;

R¹² represents OR^a, CONR^aR^b or heteroaryl;

R¹³ represents H or C₁₋₆alkyl;

R^q represents a group



where Q represents the residue of a non-aromatic azacyclic or azabicyclic ring system; and

x is 0, 1, 2 or 3.

As used herein, the definition of each expression, when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure.

The alkyl, alkenyl and alkynyl groups referred to with respect to the formulae herein may represent straight, branched or cyclic groups, or combinations thereof. Thus, for example, suitable alkyl groups include methyl, ethyl, n- or iso-propyl, n-, sec-, iso- or tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, and cycloalkyl-alkyl groups such as

cyclopropylmethyl; suitable alkenyl groups include vinyl and allyl; and suitable alkynyl groups include propargyl.

5 The term "halo" as used herein includes fluoro, chloro, bromo and iodo, especially chloro and fluoro.

 The present invention includes within its scope prodrugs of the compounds of formula (I) above. In general, such prodrugs will be functional derivatives of the compounds of formula I which are readily convertible
10 in vivo into the required compound of formula (I). Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

15 The compounds according to the invention may exist both as enantiomers and as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.

20 In one subgroup of compounds according to the invention R^3 represents H, COR^a , CO_2R^a or C_{1-6} alkyl optionally substituted by a group selected from (CO_2R^a , $CONR^{a,b}$, hydroxy, cyano, COR^a , $NR^{a,b}$, $C(NO)NR^{a,b}$, $CONHphenyl(C_{1-4}alkyl)$, $COCO_2R^a$, $COCONR^{a,b}$ and phenyl
25 optionally substituted by C_{1-6} alkyl, C_{1-6} alkoxy, halo or trifluoromethyl); and R^5 and R^6 each represent H.

 Preferably X represents O.

 Preferably m is 1.

 Preferably n is 0.

30 Preferably R^1 represents substituted phenyl.

When R^1 is substituted phenyl suitable substituents include nitro, trifluoromethyl, trimethylsilyl, bromo, chloro, fluoro, iodo, cyano, methyl, ethyl, cyclopropyl, vinyl, methoxy, phenoxy, amino and carbonylmethoxy.

Preferably R^1 represents phenyl substituted by one or more groups selected from C_{1-6} alkyl such as methyl and t-butyl, halo such as chloro, bromo and fluoro, C_{1-6} alkoxy such as methoxy and trifluoromethyl.

5 Preferably R^1 represents disubstituted phenyl, in particular 3,5-disubstituted phenyl wherein the substituents are selected from C_{1-6} alkyl, C_{1-6} alkoxy, halo and trifluoromethyl. More preferably R^1 represents 3,5-bis(trifluoromethyl)phenyl.

10 Suitable values for the group R^2 include aryl such as unsubstituted or substituted phenyl, 5-membered heteroaryl such as thienyl, 6-membered heteroaryl such as pyridyl, and benzhydryl. When R^2 represents substituted phenyl, suitable substituents include halo and
15 trifluoromethyl.

 Preferably R^2 represents unsubstituted benzhydryl, unsubstituted or substituted phenyl, thienyl, or pyridyl, more preferably unsubstituted benzhydryl, unsubstituted phenyl or phenyl substituted by halo, especially unsubstituted phenyl.
20


 Suitable values for R^3 include H, C_{1-6} alkyl, such as methyl; and CO_2R^a , such as $CO_2(C_{1-6}alkyl)$.

 Suitable values for R^4 include C_{1-6} alkyl, such as methyl, C_{1-6} alkoxy, such as methoxy, halo, such as
25 chloro and trifluoromethyl.

 Preferably x is 0.

 Preferably R^5 and R^6 independently represent H or methyl.

30 A particular sub-class of compounds according to the invention is represented by compounds of formula (Ia), and salts and prodrugs thereof:



(Ia)

10 wherein

R^2 , R^3 , R^5 , R^6 and X are as defined for formula (I);

R^{20} and R^{21} independently represent H
 C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, halo, cyano, nitro,
 15 trifluoromethyl, trimethylsilyl, OR^a, SR^a, SOR^a, SO₂R^a,
 NR^aR^b, NR^aCOR^b, NR^aCO₂R^b, COR^a or CONR^aR^b, where R^a and
 R^b are as previously defined.

Particular values of R^{20} and R^{21} include
 methyl, t-butyl, methoxy, chloro, fluoro, bromo and
 20 trifluoromethyl. Preferably R^{20} and R^{21} are both other
 than H and are located at the 3- and 5-positions of the
 phenyl ring.

For use in medicine, the salts of the compounds
 of formula (I) will be non-toxic pharmaceutically
 25 acceptable salts. Other salts may, however, be useful in
 the preparation of the compounds according to the
 invention (such as the dibenzoyltartrate salts) or of
 their non-toxic pharmaceutically acceptable salts.
 Suitable pharmaceutically acceptable salts of the
 30 compounds of this invention include acid addition salts
 which may, for example, be formed by mixing a solution of
 the compound according to the invention with a solution
 of a pharmaceutically acceptable non-toxic acid such as
 hydrochloric acid, oxalic acid, fumaric acid, maleic

acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or p-toluenesulphonic acid. Salts of amine groups may also comprise quaternary ammonium salts in which the amino
5 nitrogen atom carries a suitable organic group such as an alkyl, alkenyl, alkynyl or aralkyl moiety. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include metal salts such as alkali metal
10 salts, e.g. sodium or potassium salts; and alkaline earth metal salts, e.g. calcium or magnesium salts.

Preferred salts of the compounds according to the invention include the hydrochloride and p-toluenesulphonic acid salts.

15 The substance P antagonising activity of compounds described herein was evaluated using the human NK1R assay described in published European patent application no. 0 528 495. The method essentially involves determining the concentration of the test
20 compound required to reduce by 50% the amount of radiolabelled substance P binding to human NK1R, thereby affording an IC₅₀ value for the test compound. The compounds of the Examples were found to have IC₅₀ values less than 500nM.

25 The invention also provides pharmaceutical compositions comprising a compound of this invention in association with a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules,
30 solutions or suspensions, or suppositories, for oral, parenteral or rectal administration, or topical administration including administration by inhalation or insufflation.

For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose,
5 sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a non-
10 toxic pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally
15 effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or
20 pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by
25 an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of
30 polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil
5 suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums
10 such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatin.

Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically
15 acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as set out above. Preferably the compositions are administered by the oral or nasal respiratory route
20 for local or systemic effect. Compositions in preferably sterile pharmaceutically acceptable solvents may be nebulised by use of inert gases. Nebulised solutions may be breathed directly from the nebulising device or the nebulising device may be attached to a face mask, tent or
25 intermittent positive pressure breathing machine. Solution, suspension or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.

For topical administration, for example as a
30 cream, ointment or lotion, pharmaceutically acceptable carriers are, for example, water, mixtures of water and water-miscible solvents such as lower alkanols or arylalkanols, vegetable oils, polyalkylene glycols, petroleum based jelly, ethyl cellulose, ethyl oleate,

carboxymethylcellulose, polyvinylpyrrolidone, isopropyl myristate and other conventionally-employed non-toxic, pharmaceutically acceptable organic and inorganic carriers. The pharmaceutical preparation may also
5 contain non-toxic auxiliary substances such as emulsifying, preserving, wetting agents, bodying agents and the like, as for example, polyethylene glycols 200, 300, 400 and 600, carbowaxes 1,000, 1,500, 4,000, 6,000 and 10,000, antibacterial components such as quaternary
10 ammonium compounds, phenylmercuric salts known to have cold sterilizing properties and which are non-injurious in use, thimerosal, methyl and propyl paraben, benzyl alcohol, phenyl ethanol, buffering ingredients such as sodium chloride, sodium borate, sodium acetates,
15 gluconate buffers, and other conventional ingredients such as sorbitan monolaurate, triethanolamine, oleate, polyoxyethylene sorbitan monopalmitate, dioctyl sodium sulfosuccinate, monothioglycerol, thiosorbitol, ethylenediamine tetraacetic acid, and the like.

20 The present invention further provides a process for the preparation of a pharmaceutical composition comprising a compound of formula (I), which process comprises bringing a compound of formula (I) into association with a pharmaceutically acceptable carrier or
25 excipient.

The compounds of formula (I) are of value in the treatment of a wide variety of clinical conditions which are characterised by the presence of an excess of tachykinin, in particular substance P, activity. These
30 may include disorders of the central nervous system such as anxiety, depression, psychosis and schizophrenia; epilepsy; neurodegenerative disorders such as dementia, including senile dementia of the Alzheimer type, Alzheimer's disease and Down's syndrome; demyelinating

diseases such as MS and ALS and other neuropathological disorders such as peripheral neuropathy, including diabetic and chemotherapy-induced neuropathy, and postherpetic and other neuralgias; small cell carcinomas
5 such as small cell lung cancer; respiratory diseases, particularly those associated with excess mucus secretion such as chronic obstructive airways disease, bronchopneumonia, chronic bronchitis, cystic fibrosis and asthma, and bronchospasm; inflammatory diseases such as
10 inflammatory bowel disease, psoriasis, fibrositis, osteoarthritis and rheumatoid arthritis; allergies such as eczema and rhinitis; hypersensitivity disorders such as poison ivy; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like;
15 cutaneous diseases such as contact dermatitis, atropic dermatitis, urticaria, and other eczematoid dermatitis; addiction disorders such as alcoholism; stress related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; dysthymic disorders; adverse
20 immunological reactions such as rejection of transplanted tissues and disorders related to immune enhancement or suppression such as systemic lupus erythematosus; gastrointestinal (GI) disorders and diseases of the GI tract such as disorders associated with the neuronal
25 control of viscera such as ulcerative colitis, Crohn's disease and incontinence; emesis, including acute, delayed and anticipatory emesis, for example, induced by chemotherapy, radiation, toxins, pregnancy, vestibular disorders, surgery, migraine and variations in
30 intercranial pressure; disorders of bladder function such as bladder detrusor hyper-reflexia; fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders of blood flow caused by vasodilation and vasospastic diseases such as angina,


migraine and Reynaud's disease; and pain or nociception, for example, that attributable to or associated with any of the foregoing conditions, especially the transmission of pain in migraine.

5 The compounds of formula (I) are particularly useful in the treatment of pain or nociception and/or inflammation and disorders associated therewith such as, for example, neuropathy, such as diabetic and chemotherapy-induced neuropathy, postherpetic and other
10 neuralgias, asthma, osteoarthritis, rheumatoid arthritis and especially migraine.


 The present invention further provides a compound of formula (I), or a salt or prodrug thereof, for use in therapy.

15 In the treatment of the conditions associated with an excess of tachykinins, a suitable dosage level is about 0.001 to 50 mg/kg per day, in particular about 0.01 to about 25 mg/kg, such as from about 0.05 to about 10 mg/kg per day. For example, in the treatment of
20 conditions involving the neurotransmission of pain sensations, a suitable dosage level is about 0.001 to 25 mg/kg per day, preferably about 0.005 to 10 mg/kg per day, and especially about 0.005 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4
25 times per day, preferably once or twice per day.

 The compounds according to the invention may be prepared by a process which comprises reacting a compound of formula (III) with a compound of formula (IV):



(III)



(IV)

wherein Q, R¹, R², R⁴, R⁵, R⁶, Y, Z and x are as defined for formula (I) above, R³ is as defined for formula (I) or is a protecting group, and one of R³⁰ and R³¹ represents a leaving group and the other of R³⁰ and R³¹ represents XH, where X is as defined for formula (I); in the presence of a base.

Suitably, R³¹ represents a leaving group and R³⁰ represents XH.

Suitable leaving groups include halo, e.g. chloro, bromo or iodo, or sulphonate derivatives such as tosylate or mesylate.


The reaction is conveniently carried out in a suitable organic solvent, such as dimethyl formamide. Favoured bases of use in the reaction include alkali metal hydrides, such as sodium hydride.

Compounds of formula (I) may also be prepared from other compounds of formula (I) using suitable interconversion procedures. In particular, compounds of formula (I) wherein R³ is other than H may be prepared from compounds of formula (I) wherein R³ is H by reaction with a suitable acylating agent or optionally substituted alkylating reagent. Suitable reagents and procedures will be readily apparent to those skilled in the art.

The intermediates of formula (III) above wherein R³⁰ is SH may be prepared from the corresponding intermediates of formula (III) wherein R³⁰ represents OH by treating the latter compound with Lawesson's reagent

or phosphorus pentasulphide in a suitable solvent, e.g. pyridine, at ambient or elevated temperatures, suitably at reflux temperature.

- 5 The intermediates of formula (III) above wherein R^{30} is OH and n is 1 may be prepared by reduction of a compound of formula (V):




(V)

- 15 wherein R^2 , R^3 , R^4 , Y and x are as defined for formula (III).

The reaction is suitably effected by means of hydrogenation in the presence of a suitable catalyst, such as a nobel metal catalyst, for example, palladium, which may be supported, for example, on carbon.

20 Intermediates of formula (III) wherein R^{30} is OH, n is 0, and m is 1 may be prepared by reduction of compounds of formula (VI).



(VI)


wherein R^2 , R^3 , R^4 and x are as defined for formula (III).

Suitable reducing agents of use in the reaction include borane.

Intermediates of formula (III) wherein R^{30} is a leaving group may be prepared from compounds of formula (III) wherein R^{30} is OH, for example, by reaction with a thionyl halide, a mesyl halide or a tosyl halide.

5 Where they are not commercially available, the intermediates of formula (IV) above may be prepared by conventional procedures which will be readily apparent to one skilled in the art.

10 Compounds of formula (V) may be prepared by epoxidation of the corresponding alkenes of formula (VII)




(VII)

20 wherein R^2 , R^3 , R^4 , Y and x are as defined for formula (III).

The reaction is conveniently effected using a peracid, for example, m-chloroperbenzoic acid (m-CPBA), and an alkali or alkaline earth metal carbonate, for example, sodium bicarbonate, in a suitable organic solvent, such as a halogenated hydrocarbon, for example, dichloromethane. The epoxidation is preferably effected at low temperature, such as approximately 0°C.

25 Compounds of formula (VII) wherein R^3 is H may be prepared from compounds of formula (VIII)

30




(VIII)


by reaction with a reagent of formula R^2-M , where R^2 is
 10 as defined for formula (I) and M represents an alkali
 metal, such as lithium.

Compounds of formula (VI) may be prepared by
 reaction of a compound of formula (IX) with a compound of
 formula (X)

15



(IX)



(X)

wherein R^2 , R^3 , R^4 and x are as defined for formula (III)
 25 and G represents a protecting group, in the presence of a
 base, followed by deprotection.

Suitable bases of use in the reaction include
 butyl lithiums.

Compounds of formula (VII) wherein R^3 is other
 30 than H may be prepared from the corresponding compounds
 wherein R^3 is H by conventional procedures.

Compounds of formula (VIII) are commercially
 available or may be prepared from commercially available
 starting materials by known processes.

Where the above-described process for the preparation of the compounds according to the invention gives rise to mixtures of stereoisomers these isomers may, if desired, be separated, suitably by conventional techniques such as preparative chromatography.

The novel compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. For example, intermediate alcohols of formula (III), wherein X is oxa, may be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. The diastereomeric alcohols can then be used to prepare optically pure compounds of formula (I).

During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

The following examples illustrate the preparation of compounds according to the invention.

EXAMPLE 1N-t-Butoxycarbonyl-2-phenyl-3-((3,5-bis(trifluoromethyl)phenyl)methoxy)-2,3,4-trihydroquinoline

5 a) To a solution of quinoline (6g) in diethyl ether (60ml) was added a solution of phenyllithium (40ml, 1.8M) in diethyl ether/cyclohexane) at room temperature. After 2 min the temperature was lowered to -78°C and a solution of di-t-butylidicarbonate (20.3g) in diethyl ether (20ml) was added. The temperature was allowed to rise to room temperature over 3 h and the solution was stirred for a further 16 h. Diethyl ether (100ml) was added and the solution was washed with water. The organic layer was dried (Na₂SO₄) and the solvent removed *in vacuo* to give N-t-butoxycarbonyl-2-phenyl-2-hydroquinoline. ¹H NMR (250MHz, CDCl₃) δ 6.95-7.6 (9H, m), 6.6 (1H, m), 6.15 (2H, m).

15 b) m-Chloroperbenzoic acid (10.2g) was added in small portions to a mixture of N-t-butoxycarbonyl-2-phenyl-2-hydroquinoline (Example 1a) and sodium bicarbonate (40g) in dichloromethane (600ml) at 0°C. After stirring at room temperature for 5h m-chloroperbenzoic acid (10.5g) was added and the solution was stirred for 16 h. The solution was washed with water and dried (Na₂SO₄). Removal of the solvent *in vacuo* gave an oil which was chromatographed on silica gel in dichloromethane/ethyl acetate/petrol (10:10:80) to give N-t-butoxycarbonyl-2-phenyl-3,4-epoxy-2,3,4-trihydroquinoline (11.2g). ¹H NMR (250MHz, CDCl₃) δ 7.15-7.42 (9H, m), 6.15 (1H, s), 3.98-4.10 (2H, m), 1.50 (9H, s).

25 c) N-t-butoxycarbonyl-2-phenyl-3,4-epoxy-2,3,4-trihydroquinoline (11.2g) was hydrogenated over 10% palladium on charcoal in ethanol (800ml) at 45 psi for 15 min. The solution was filtered and the solvent was removed *in vacuo* to give N-t-

30

butoxycarbonyl-2-phenyl-3-hydroxy-2,3,4-trihydroquinoline
(7.93g). ^1H NMR (360MHz, CDCl_3) δ 7.87 (1H, d, $J = 8.2\text{Hz}$),
7.02-7.29 (8H, m), 5.19 (1H, d, $J = 5.9\text{Hz}$), 4.01 (1H, m), 2.82
(2H, m), 1.36 (9H, s). m/z (CI^+) 326 ($\text{M}+\text{H}$).

- 5 d) Sodium hydride (0.43g, 60% suspension in oil) was added
to a solution of N-t-butoxycarbonyl-2-phenyl-3-hydroxy-2,3,4-
trihydroquinoline (3g) in dimethylformamide (15ml) at 0°C .
After stirring for 30 min 3,5-bis(trifluoromethyl)benzyl bromide
10 (4.24g) was added and the solution was stirred at room
temperature for 3 h. The solution was poured into a saturated
ammonium chloride solution and extracted with ethyl acetate.
The organic layer was washed with water (x 2) and dried
(Na_2SO_4). Removal of the solvent *in vacuo* gave an orange oil
which was chromatographed on silica gel in ethyl acetate/petrol
15 (1:9) to give the title compound (4.36g) after recrystallisation
from petrol ($60-80^\circ$). ^1H NMR (360MHz, CDCl_3) δ 7.76 (1H, m),
7.69 (2H, s), 7.03-7.29 (8H, m), 5.42 (1H, d, $J = 5.7\text{Hz}$), 4.72 (1H,
d, $J = 12.4\text{Hz}$), 4.57 (1H, d, $J = 12.4\text{Hz}$), 3.83 (1H, m), 2.81-2.96
(2H, m), 1.36 (9H, s). m/z (CI^+) 552 ($\text{M}+\text{H}$). Found: C, 62.69; H,
20 4.97; N, 2.53. $\text{C}_{29}\text{H}_{27}\text{NO}_3\text{F}_6$ requires C, 63.15; H, 4.93; N, 2.54.

EXAMPLE 2

- 25 2-Phenyl-3-((3,5-bis(trifluoromethyl)phenyl)methoxy)-
1,2,3,4-tetrahydroquinoline hydrochloride salt

- 30 The compound of Example 1 (3g) was dissolved in
trifluoroacetic acid (30ml) and the resulting solution was stirred
for 15 min. The excess trifluoroacetic acid was removed *in vacuo*
and the residue was dissolved in dichloromethane, washed with
(a) 2N sodium hydroxide and (b) water. The organic layer was
dried (Na_2SO_4). The solvent was removed *in vacuo* and the

residue was dissolved in diethyl ether and excess ethereal-hydrogen chloride was added. The resulting solid was filtered and after recrystallisation from ethyl acetate/methanol gave 2-phenyl-3-((3,5-bis(trifluoromethyl)phenyl)methoxy)-1,2,3,4-tetrahydroquinoline hydrochloride salt (2.23g). ¹H NMR

(360MHz, CDCl₃) δ 7.93 (1H, s), 7.75 (1H, s), 7.38 (5H, m), 6.92 (2H, m), 6.51-6.63 (2H, m), 4.80 (1H, d, J = 12.9Hz), 4.59 (1H, d, J = 12.9Hz), 4.42 (1H, d, 6.2Hz), 3.88-3.93 (1H, m), 2.88 (1H, dd, J = 4.9Hz), 2.81 (1H, dd, J = 7.5Hz). m/z (CI⁺) 452 (M+H).

Found: C, 57.61; H, 4.13; N, 2.75. C₂₄H₂₀NOClF₈·0.7H₂O requires C, 57.59; H, 4.31; N, 2.79.

The following examples illustrate pharmaceutical compositions according to the invention.

EXAMPLE 3A Tablets containing 1-25mg of compound

5		<u>Amount mg</u>		
	Compound of formula (I)	1.0	2.0	25.0
	Microcrystalline cellulose	20.0	20.0	20.0
	Modified food corn starch	20.0	20.0	20.0
	Lactose	58.5	57.5	34.5
10	Magnesium Stearate	0.5	0.5	0.5

EXAMPLE 3B Tablets containing 26-100mg of compound

		<u>Amount mg</u>		
	Compound of formula (I)	26.0	50.0	100.0
15	Microcrystalline cellulose	80.0	80.0	80.0
	Modified food corn starch	80.0	80.0	80.0
	Lactose	213.5	189.5	139.5
	Magnesium Stearate	0.5	0.5	0.5
20	The compound of formula (I), cellulose, lactose and a portion of the corn starch are mixed and granulated with 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing			
25	1.0mg, 2.0mg, 25.0mg, 26.0mg, 50.0mg and 100mg of the active compound per tablet.			

EXAMPLE 4 Parenteral injection

		<u>Amount mg</u>
30	Compound of formula (I)	1 to 100mg
	Citric Acid Monohydrate	0.75mg
	Sodium Phosphate	4.5mg
	Sodium Chloride	9mg
	Water for Injections	to 1ml

The sodium phosphate, citric acid monohydrate and sodium chloride are dissolved in a portion of the water. The compound of formula (I) is dissolved or suspended in the solution and made up to volume.

5

EXAMPLE 5 Topical formulation


	<u>Amount mg</u>
Compound of formula (I)	1-10g
Emulsifying Wax	30g
10 Liquid paraffin	20g
White Soft Paraffin	to 100g

The white soft paraffin is heated until molten. The liquid paraffin and emulsifying wax are incorporated and stirred until dissolved. The compound of formula (I) is added and stirring continued until dispersed. The mixture is then cooled until solid.

15

CLAIMS:

1. A compound of formula (I), or a salt or
5 prodrug thereof:



(I)

15 wherein

X represents O or S;

Y represents $(CH_2)_m$, where m is 0 or 1;

Z represents $(CH_2)_n$, where n is 0 or 1;

20 R^1 represents phenyl optionally substituted by
1, 2 or 3 groups selected from C_{1-6} alkyl, C_{2-6} alkenyl,
 C_{2-6} alkynyl, halo, cyano, nitro, trifluoromethyl,
trimethylsilyl, $-OR^a$, SR^a , SOR^a , SO_2R^a , $-NR^aR^b$, $-NR^aCOR^b$,
 $-NR^aCO_2R^b$, $-CO_2R^a$ and $-CONR^aR^b$;

25 R^2 represents aryl selected from phenyl and
naphthyl; heteroaryl selected from indazolyl, thienyl,
furyl, pyridyl, thiazolyl, tetrazolyl and quinolyl;
benzhydryl; or benzyl; wherein each aryl or heteroaryl
moiety may be substituted by C_{1-6} alkyl, C_{1-6} alkoxy, halo
or trifluoromethyl;

30 R^3 represents H, COR^a , CO_2R^a , $C(COOR^a)_2$,
 $C(CONR^aR^b)_2$, $COCONR^aR^b$, $COCO_2R^a$, C_{1-6} alkyl optionally
substituted by a group selected from $(CO_2R^a$, $CONR^aR^b$,
hydroxy, cyano, COR^a , NR^aR^b , $C(NOH)NR^aR^b$,
 $CONHphenyl(C_{1-4}alkyl)$, $COCO_2R^a$, $C(=NR^a)NR^bNR^cCO_2R^d$,

- CONHN^aR^b, C(S)NR^aR^b, CONR^aC₁₋₆alkylR¹²,
 CONR¹³C₂₋₆alkynyl, CONR¹³C₂₋₆alkenyl, COCONR^aR^b,
 CONR^aC(NR^b)NR^cR^d, CONR¹³SO₂R^a, SO₂R¹³COR^a, COR^q,
 CONR^aheteroaryl, and phenyl optionally substituted by one
 5 or more substituents selected from C₁₋₆alkyl, C₁₋₆alkoxy,
 halo and trifluoromethyl) or C₁₋₆alkyl, optionally
 substituted by oxo, substituted by an optionally
 substituted aromatic heterocycle;
 Each R⁴ independently represents halo,
 10 C₁₋₆alkyl, C₁₋₆alkoxy or trifluoromethyl;
 R⁵ and R⁶ each independently represent H or
 C₁₋₆alkyl;
 R^a, R^b, R^c and R^d each independently represent
 H, C₁₋₆alkyl, phenyl or trifluoromethyl;
 15 R¹² represents OR^a, CONR^aR^b or heteroaryl;
 R¹³ represents H or C₁₋₆alkyl;
 R^q represents a group



- where Q represents the residue of a non-aromatic
 25 azacyclic or azabicyclic ring system; and
 x is 0, 1, 2 or 3.

2. A compound as claimed in claim 1 wherein
 R³ represents H, COR^a, CO₂R^a or C₁₋₆alkyl optionally
 30 substituted by a group selected from (CO₂R^a, CONR^aR^b,
 hydroxy, cyano, COR^a, NR^aR^b, C(NOH)NR^aR^b,
 CONHphenyl(C₁₋₄alkyl), COCO₂R^a, COCONR^aR^b and phenyl
 optionally substituted by C₁₋₆alkyl, C₁₋₆alkoxy, halo or
 trifluoromethyl); and R⁵ and R⁶ each represent H.

3. A compound as claimed in claim 1 or claim 2 wherein X is O.

5 4. A compound as claimed in any preceding claim wherein m is 1 and n is 0.

10 5. A compound as claimed in any preceding claim wherein R¹ represents phenyl substituted by one or more groups selected from C₁₋₆alkyl, halo, C₁₋₆alkoxy and trifluoromethyl.

15 6. A compound as claimed in any preceding claim wherein R² represents unsubstituted benzhydryl, unsubstituted phenyl or phenyl substituted by halo.

7. A compound as claimed in any preceding claim wherein R³ is H, C₁₋₆alkyl or CO₂R^a.

20 8. A compound as claimed in any preceding claim wherein R⁵ and R⁶ each independently represent H or methyl.

25 9. A compound as claimed in claim 1 selected from:

N-t-butoxycarbonyl-2-phenyl-3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2,3,4-trihydroquinoline;
2-phenyl-3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-
30 1,2,3,4-tetrahydroquinoline;
and salts and prodrugs thereof.

10. A compound as claimed in any preceding claim for use in therapy.

11. A pharmaceutical composition comprising a compound as claimed in any of claims 1 to 9 in association with a pharmaceutically acceptable carrier.

5 12. The use of a compound as claimed in claim 1 for the manufacture of a medicament for the treatment of a physiological disorder associated with an excess of tachykinins.

10 13. The use of a compound as claimed in claim 1 for the manufacture of a medicament for the treatment of pain or inflammation.

- 28 -

Patents Act 1977 Examiner's report to the Comptroller under Section 17 (The Search report)		Application number GB 9315962.2
Relevant Technical Fields (i) UK Cl (Ed.L) C2C CBE CWE (ii) Int Cl (Ed.5) C07D		Search Examiner D S LUCAS
		Date of completion of Search 20 OCTOBER 1993
Databases (see below) (i) UK Patent Office collections of GB, EP, WO and US patent specifications. (ii) ONLINE DATABASE: CAS ONLINE		Documents considered relevant following a search in respect of Claims :- 1-13

Categories of documents

- | | |
|---|---|
| X: Document indicating lack of novelty or of inventive step. | P: Document published on or after the declared priority date but before the filing date of the present application. |
| Y: Document indicating lack of inventive step if combined with one or more other documents of the same category. | E: Patent document published on or after, but with priority date earlier than, the filing date of the present application. |
| A: Document indicating technological background and/or state of the art. | &: Member of the same patent family; corresponding document. |

Category	Identity of document and relevant passages	Relevant to claim(s)
	None	

Databases: The UK Patent Office database comprises classified collections of GB, EP, WO and US patent specifications as outlined periodically in the Official Journal (Patents). The on-line databases considered for search are also listed periodically in the Official Journal (Patents).

